Fusion Pharmaceuticals to Present at the Guggenheim Securities Radiopharmaceuticals Day
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) announced its participation in a fireside chat at Guggenheim Securities Radiopharmaceuticals Day on May 17, 2022, at 3:00 p.m. ET. CEO John Valliant, Ph.D., will present. A live webcast will be available on the Company's website, with a replay accessible for 60 days. Fusion focuses on developing next-generation radiopharmaceuticals and has ongoing clinical trials, including FPI-1434 and FPI-1966. The company also collaborates with AstraZeneca and Merck to enhance targeted therapy programs.
- None.
- None.
HAMILTON, ON and BOSTON, May 11, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in a fireside chat at the Guggenheim Securities Radiopharmaceuticals Day in New York, New York on Tuesday, May 17, 2022 at 3:00 p.m. ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.
A live webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 60 days following the presentation.
About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434 targeting insulin-like growth factor 1 receptor, is currently in a Phase 1 clinical trial. The pipeline includes FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3), advancing to a Phase 1 study following the recent investigational new drug (IND) clearance; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1). In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Repair Inhibitors (DDRis) and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. Fusion and Hamilton, Ontario-based McMaster University are building a current Good Manufacturing Practice (GMP) compliant radiopharmaceutical manufacturing facility designed to support manufacturing of the Company's growing pipeline of TATs.
For further information: Amanda Cray, Senior Director of Investor Relations & Corporate Communications, 617-967-0207, cray@fusionpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-guggenheim-securities-radiopharmaceuticals-day-301545338.html
SOURCE Fusion Pharmaceuticals Inc.
FAQ
What event will Fusion Pharmaceuticals participate in on May 17, 2022?
Who will represent Fusion Pharmaceuticals at the Guggenheim event?
Where can I watch the Fusion Pharmaceuticals fireside chat?
What is the focus of Fusion Pharmaceuticals' research?
What are the key programs in Fusion Pharmaceuticals' pipeline?
How long will the webcast of the event be available for replay?
